Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
TESARO, Inc. logo — company profile

TESARO, Inc.

Founded 2010 United States Waltham, United States 62 employees Post Ipo Equity Total: $1.10B Biopharma, Biotechnology +1

General Information

Company Name TESARO, Inc.
Founded Year 2010
Location United States Waltham, United States +7
Founders / Decision Makers
Team member
Employees 62
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when TESARO, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TESARO, Inc.

TESARO, Inc. is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission dedicated to improving the oncology experience. The company's commitment to unconditional care puts science for patients first. Founded in 2010 and headquartered in the United States, TESARO operates within the Biopharma, Biotechnology, and Health Care industries. Notably, the company received a significant $409.00M post-IPO equity investment on 30 June 2016. This investment reflects investor confidence in TESARO's mission and potential for future growth. As a part of GSK, TESARO is committed to inspiring future leaders and building lasting careers, creating a work environment that enables the team to provide unconditional care for people living with cancer.

Taxonomy: oncology-focused, biopharmaceuticals, drug development, cancer treatment, neurokinin-1 receptor antagonist, chemotherapy induced nausea and vomiting, Phase 2 clinical testing, Phase 3 clinical testing, ALK inhibitor program, drug candidates, commercialization, MGI PHARMA, Eisai Co., Ltd., Waltham, Massachusetts

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 30 Jun 2016
Post-IPO Equity •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		10 Mar 2016
Post-IPO Equity •••••• - 02 Mar 2015
Post-IPO Equity •••••• - 28 Jan 2014
Post-IPO Equity •••••• - 06 Mar 2013

View All 8 Funding Rounds

TESARO, Inc. Alternatives & Competitors

TESARO, Inc. vs
TRIO - Translational Research in Oncology
TRIO - Translational Research in Oncology Canada

Advancing cancer research. Life-changing results.

246 employees
Biotechnology, Health Care
Compare TESARO, Inc. vs TRIO - Translational Research in Oncology
TESARO, Inc. vs
OnQuality Pharmaceuticals Ltd.
OnQuality Pharmaceuticals Ltd. China

developing innovative drugs and drug delivery systems that improve the quality of life of oncology p...

Series A
7 employees
Biopharma, Biotechnology
Compare TESARO, Inc. vs OnQuality Pharmaceuticals Ltd.
TESARO, Inc. vs
Medelis, Inc.
Medelis, Inc. United States

A specialty oncology CRO and a pioneer in immunotherapy studies.

28 employees
Biotechnology, Pharmaceutical
Compare TESARO, Inc. vs Medelis, Inc.

FAQ About TESARO, Inc.

TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our actions. We are dedicated to improving the oncology experience and have a passionate commitment to unconditional care, which puts science for patients first. At TESARO, we bring together w...
TESARO, Inc. was founded in 2010.
TESARO, Inc. is headquartered in Waltham, United States.
TESARO, Inc. operates in the following industries: Biopharma, Biotechnology, Health Care.
TESARO, Inc. has approximately 62 employees.
TESARO, Inc. has completed 8 funding rounds, raising a total of $1.10B. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to TESARO, Inc. include TRIO - Translational Research in Oncology, OnQuality Pharmaceuticals Ltd., Medelis, Inc., Charles River Laboratories, Simbec-Orion. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TESARO, Inc. and TRIO - Translational Research in Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TESARO, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy